NeOnc Technologies Holdings, Inc. (NTHI)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Amir Farrokh Heshmatpour
|
President, CEO, Executive Chairman & Secretary | -- | -- | 1967 |
|
Dr. Thomas C. Chen M.D., Ph.D.
|
Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman | 212k | -- | 1965 |
|
Mr. Keithly A. Garnett
|
Chief Financial Officer | 179k | -- | 1975 |
|
Dr. Josh Neman-Ebrahim Ph.D.
|
Chief Clinical Officer | 165k | -- | 1978 |
|
Mr. David Choi Jr.
|
Chief Accounting Officer | -- | -- | -- |
NeOnc Technologies Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
NeOnc Technologies Holdings, Inc. Earnings Date
